New Findings Could Change the Everyday Treatment of Patients With Advanced Prostate Cancer
DANIEL J. GEORGE, MD
Wednesday, October 02, 2019
At the European Society of Medical Oncology 2019, Congress researchers discussed the latest results of the CARD study, which is a phase 4 clinical trial comparing the chemotherapy agent cabazitaxel (Jevtana) and an androgen receptor, either abiraterone (Zytiga) or enzalutamide (Xtandi), in patients with advanced prostate cancer. New findings showed stronger rates of survival for those on cabazitaxel.
OncLive®, a sister publication of Oncology Nursing News®, had the chance to sit down with Daniel J. George, MD, professor of medicine and surgery and director of GU Oncology at the Duke Cancer Institute, to discuss what these findings mean for the treatment of patients.
For me, in my practice looking at this data now, I'm going to be more compelled to say when I've treated somebody with an androgen receptor-targeted agent, whether they've had chemotherapy or not, I'm going to use chemotherapy. Then, when they progress on that, then this is an agent that has a proven survival benefit.
What's difficult is looking at other agents in common, such as radium-223 (Xofigo)and where that falls, and I think we're going to want to see more data with other agents in here. At least as far as cabazitaxel goes we know that now we have a second study demonstrating, in the contemporary setting, a survival benefit to that sequence.